In 2015, 15.1 million adults (18 and older), had Alcohol Use Disorder; while only 1.3 million received treatment. This treatment gap has led to an estimated 88,000 people dying from alcohol related causes annually. Accordingly, alcohol remains the most abused and most deadly drug among substance use disorders.
Like other drugs, heavy alcohol use can lead to tolerance, dependence, and even abuse which may require treatment. Patients that abuse alcohol experience severe withdrawals including dangerous ‘delirium tremens’ (DTs) which is marked by confusion, shivering, sweating, irregular heartbeat, and even seizures. Harmful drinking may be reduced or even eliminated with a combination of medication, counseling, and peer support.
Pathway Healthcare’s proprietary approach, MAT Plus®, addresses alcohol use disorder at all levels using a holistic, multi-disciplined approach that incorporates medical and behavioral therapies. By combining medication assisted treatment and focused, patient specific counseling in the outpatient setting, MAT Plus® packages the latest evidence-based treatments for alcohol abuse to produce the best outcomes.
Medication like Vivitrol, Naltrexone, and Acamprosate, in combination with a comprehensive alcohol treatment program, have been shown to be effective in the treatment of alcohol abuse. These medications work on various aspects of alcohol dependence or abuse; some helping with cravings, some blocking euphoric effects of alcohol to dissuade future consumption.
Counseling is an integral part of Pathway Healthcare’s MAT Plus® treatment program. Medication alone is helpful, but positive outcomes are improved when paired with individual, patient specific counseling. Patients will enjoy our ongoing behavioral counseling, through our outpatient services. Additionally, through our partner network, patients will have access to community, faith based, and intensive outpatient services.
About Naltrexone, Vivitrol and Acamprosate
Naltrexone/Vivitrol blocks the reward of alcohol and opioids. When alcohol and drug use continue while on naltrexone/vivitrol, there is no associated reward and deconditioning occurs.
To learn more about Vivitrol, click here.
Acamprosate has been shown in clinical trials to reduce heavy, harmful drinking to a less harmful level. The exact mechanism of Acamprosate is unknown but it is thought to restore balance in the brain’s motivation/reward centers.
To learn more about Acamprosate, click here.